Balchem Co. (NASDAQ:BCPC - Free Report) - Equities research analysts at Sidoti Csr lowered their Q1 2026 earnings per share (EPS) estimates for shares of Balchem in a research note issued to investors on Wednesday, October 9th. Sidoti Csr analyst K. May now anticipates that the basic materials company will post earnings per share of $1.26 for the quarter, down from their prior forecast of $1.28. The consensus estimate for Balchem's current full-year earnings is $3.96 per share. Sidoti Csr also issued estimates for Balchem's Q2 2026 earnings at $1.29 EPS, Q3 2026 earnings at $1.31 EPS and FY2026 earnings at $5.15 EPS.
A number of other research firms have also recently weighed in on BCPC. HC Wainwright raised their price objective on shares of Balchem from $170.00 to $185.00 and gave the stock a "buy" rating in a report on Wednesday, July 31st. StockNews.com cut shares of Balchem from a "buy" rating to a "hold" rating in a report on Monday, July 29th.
Read Our Latest Stock Analysis on BCPC
Balchem Stock Down 1.0 %
Balchem stock traded down $1.80 during midday trading on Thursday, reaching $170.18. The company's stock had a trading volume of 100,950 shares, compared to its average volume of 107,049. The company has a quick ratio of 1.79, a current ratio of 2.83 and a debt-to-equity ratio of 0.26. Balchem has a fifty-two week low of $110.74 and a fifty-two week high of $186.03. The company has a market cap of $5.52 billion, a P/E ratio of 47.73, a P/E/G ratio of 5.54 and a beta of 0.65. The business has a 50-day simple moving average of $170.77 and a 200-day simple moving average of $160.85.
Balchem (NASDAQ:BCPC - Get Free Report) last issued its quarterly earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.95 by $0.03. Balchem had a net margin of 12.52% and a return on equity of 10.94%. The company had revenue of $234.08 million during the quarter, compared to the consensus estimate of $241.26 million.
Insider Activity
In related news, SVP Gunsteren Job Leonard Van sold 7,750 shares of Balchem stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total value of $1,395,387.50. Following the sale, the senior vice president now directly owns 8,540 shares in the company, valued at $1,537,627. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.25% of the company's stock.
Institutional Trading of Balchem
Several large investors have recently modified their holdings of BCPC. Envestnet Portfolio Solutions Inc. raised its stake in Balchem by 1.5% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 3,926 shares of the basic materials company's stock valued at $604,000 after purchasing an additional 59 shares during the last quarter. Inspire Investing LLC boosted its holdings in shares of Balchem by 2.7% in the 3rd quarter. Inspire Investing LLC now owns 2,348 shares of the basic materials company's stock valued at $413,000 after purchasing an additional 62 shares during the last quarter. GAMMA Investing LLC grew its position in Balchem by 18.0% during the first quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company's stock valued at $73,000 after acquiring an additional 72 shares during the period. Hsbc Holdings PLC grew its holdings in shares of Balchem by 1.5% during the 2nd quarter. Hsbc Holdings PLC now owns 4,915 shares of the basic materials company's stock worth $757,000 after purchasing an additional 75 shares during the period. Finally, Atomi Financial Group Inc. increased its position in shares of Balchem by 6.1% in the third quarter. Atomi Financial Group Inc. now owns 1,674 shares of the basic materials company's stock worth $295,000 after acquiring an additional 96 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors and hedge funds.
Balchem Company Profile
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
See Also
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
